Compare iShares Core High Dividend ETF (HDV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Pfizer Inc — how do they compare? iShares Core High Dividend ETF trades at $28.78 (market cap $14.72B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 10.8× iShares Core High Dividend ETF's market cap, and Pfizer Inc pays a 6.14% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Pfizer Inc for 158 Days on average.
| HDV | PFE | |
|---|---|---|
Market Cap | $14.72B | $159.59B |
Volume | 2,297,177 | 30,937,010 |
52-Week High | $29.93 | $29.02 |
52-Week Low | $23.64 | $23.67 |
Typical Hold Time | 117 Days | 158 Days |
Sector | — | Health |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% with neutral technical signals. The ETF recently underwent significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. Technical indicators show mixed signals with bearish moving averages but neutral oscillators. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the fund's 3% yield may not fully compensate for increased concentration risks.
The outlook remains cautious as HDV's sector concentration (62% in three sectors) creates heightened risk exposure. While the dividend yield provides income stability, the fund's recent underperformance relative to peers and reduced diversification warrant careful monitoring. Investors should weigh the trade-off between current income and long-term growth potential given the significant portfolio restructuring.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
